MAPK/ERK pathway

MAPK/ERK pathway. The MAPK/ERK pathway, a highly conserved signal transduction cascade, is a primary mechanism for communicating extracellular signals to the nucleus to influence fundamental cellular processes. It is classically activated by growth factors binding to Receptor tyrosine kinases, initiating a phosphorylation relay through core kinases. Dysregulation of this pathway is a hallmark of numerous diseases, most notably a wide spectrum of human cancers.

Overview

The pathway, often termed the RAS-MAPK pathway, is a critical intracellular communication network present in all eukaryotic organisms. Its discovery and elucidation were pivotal achievements in Cell biology, with foundational contributions from researchers like Michael J. Weber and Robert A. Weinberg. The canonical cascade transmits signals from the cell surface via a sequential kinase module: RAS activates RAF kinase, which phosphorylates and activates MEK, which in turn activates ERK. This final kinase, ERK, then phosphorylates a vast array of substrates in the Cytoplasm and nucleus, thereby regulating processes such as Gene expression, Cell proliferation, and Cell differentiation.

Components and activation

Activation typically begins when a ligand, such as Epidermal growth factor or Fibroblast growth factor, binds to its cognate Receptor tyrosine kinase on the Cell membrane. This binding induces Dimerization and Autophosphorylation of the receptor, creating docking sites for adaptor proteins like GRB2 and the Guanine nucleotide exchange factor SOS1. The SOS1 protein facilitates the exchange of GDP for GTP on the small GTPase RAS, transitioning it to its active state. Active GTP-bound RAS then recruits RAF kinase (e.g., BRAF) to the membrane, triggering a conformational change and RAF kinase activation. Subsequently, RAF kinase phosphorylates the dual-specificity kinases MEK1 and MEK2, which then phosphorylate the Mitogen-activated protein kinases ERK1 and ERK2 on both threonine and tyrosine residues, fully activating them.

Biological functions

Once activated, ERK influences a diverse set of biological functions by phosphorylating over 160 substrates. In the Cytoplasm, it targets proteins involved in translation, such as MNK1, and Apoptosis regulators like BAD. Its translocation into the nucleus is a key event, where it phosphorylates Transcription factors including ELK1, c-Fos, and c-Myc, modulating programs for Cell cycle progression. The pathway is essential for normal Embryogenesis, as demonstrated in model organisms like Drosophila melanogaster and Mus musculus, and plays a central role in Cell differentiation in tissues such as the Nervous system and Immune system. It also contributes to Cell motility and Cytoskeleton reorganization.

Regulation

The pathway is tightly controlled by multiple negative feedback mechanisms to prevent excessive signaling. Key regulators include Dual-specificity phosphatases like DUSP6, which dephosphorylate and inactivate ERK. SPRY2 and other Sprouty proteins inhibit the activation of RAS or RAF kinase. Furthermore, activated ERK can phosphorylate SOS1 and RAF kinase, creating feedback inhibition loops. The spatial organization of signaling is also regulated by Scaffold proteins, such as those in the KSR1 family, which assemble the kinase components to enhance specificity and efficiency. The Ubiquitin-proteasome system, involving E3 ubiquitin ligases like CBL, downregulates activated receptors.

Role in disease

Aberrant activation of the pathway is a major driver of oncogenesis. Gain-of-function mutations in genes encoding RAS are found in approximately 30% of all human cancers, including Pancreatic cancer, Colorectal cancer, and Lung cancer. Mutations in BRAF, notably the V600E mutation, are prevalent in Melanoma, Hairy cell leukemia, and Papillary thyroid carcinoma. Germline mutations in pathway components cause a class of developmental disorders known as RASopathies, which include Noonan syndrome, Cardiofaciocutaneous syndrome, and Costello syndrome. These conditions are characterized by distinctive facial features, Heart defects, and increased cancer risk.

Research and therapeutic targeting

The pathway is a major focus of Cancer research and Drug discovery. Successful therapeutic strategies have targeted hyperactive nodes, most notably with the development of BRAF inhibitors like Vemurafenib and Dabrafenib for treating Melanoma. These are often combined with MEK inhibitors such as Trametinib or Cobimetinib to overcome resistance. Direct inhibition of RAS has historically been challenging, but recent breakthroughs like the KRAS G12C inhibitor Sotorasib represent a new era. Ongoing research explores Allosteric inhibitors, combination therapies with Immune checkpoint inhibitors like Pembrolizumab, and targeting downstream Transcription factors. Studies in model systems, including Caenorhabditis elegans and Xenopus laevis, continue to reveal novel regulatory aspects. Category:Cell signaling Category:Signal transduction Category:Oncogenes